Cargando…

Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants

The recent pandemic of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has raised global health concerns. The viral 3-chymotrypsin-like cysteine protease (3CL(pro)) enzyme controls coronavirus replication and is essential for its life cycle. 3CL(pro) is a proven drug discovery target in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tahir ul Qamar, Muhammad, Alqahtani, Safar M., Alamri, Mubarak A., Chen, Ling-Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Xi'an Jiaotong University 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156227/ https://www.ncbi.nlm.nih.gov/pubmed/32296570 http://dx.doi.org/10.1016/j.jpha.2020.03.009

Ejemplares similares

Discovery of human coronaviruses pan-papain-like protease inhibitors using computational approaches
por: Alamri, Mubarak A., et al.
Publicado: (2020)

Discovery of anti-MERS-CoV small covalent inhibitors through pharmacophore modeling, covalent docking and molecular dynamics simulation
por: Alamri, Mubarak A., et al.
Publicado: (2021)

Molecular and Structural Analysis of Specific Mutations from Saudi Isolates of SARS-CoV-2 RNA-Dependent RNA Polymerase and their Implications on Protein Structure and Drug–Protein Binding
por: Alamri, Mubarak A., et al.
Publicado: (2022)

Network pharmacology based virtual screening of Flavonoids from Dodonea angustifolia and the molecular mechanism against inflammation
por: Alamri, Mubarak A., et al.
Publicado: (2023)

Structure-based virtual screening and molecular dynamics of phytochemicals derived from Saudi medicinal plants to identify potential COVID-19 therapeutics
por: Alamri, Mubarak A., et al.
Publicado: (2020)

Identification of phytochemical inhibitors of SARS-CoV-2 protease 3CL(pro) from selected medicinal plants as per molecular docking, bond energies and amino acid binding energies
por: Ullah, Sami, et al.
Publicado: (2022)

Inhibition of the SARS-CoV-2 3CL(pro) main protease by plant polyphenols
por: Bahun, Miha, et al.
Publicado: (2022)

Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro)
por: Du, Ruikun, et al.
Publicado: (2021)

Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

An integrated computational approach towards novel drugs discovery against polyketide synthase 13 thioesterase domain of Mycobacterium tuberculosis
por: Altharawi, Ali, et al.
Publicado: (2023)

Profiling of Substrate Specificity of SARS-CoV 3CL(pro)
por: Chuck, Chi-Pang, et al.
Publicado: (2010)

Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL(pro) inhibitors for treating COVID-19
por: Zhang, Jian-Wei, et al.
Publicado: (2022)

Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

Epitope‐based peptide vaccine design and target site depiction against Middle East Respiratory Syndrome Coronavirus: an immune-informatics study
por: Tahir ul Qamar, Muhammad, et al.
Publicado: (2019)

Structural Elucidation of Rift Valley Fever Virus L Protein towards the Discovery of Its Potential Inhibitors
por: Alamri, Mubarak A., et al.
Publicado: (2022)

Targeting non-structural proteins and 3CL(pro) in SARS-CoV-2 virus using phytochemicals from medicinal plants - In-silico approach
por: Rajaram, Haritha, et al.
Publicado: (2022)

Discovery of Novel Inhibitors From Medicinal Plants for V-Domain Ig Suppressor of T-Cell Activation
por: Muneer, Iqra, et al.
Publicado: (2021)

Protocol for production and purification of SARS-CoV-2 3CL(pro)
por: Mazzei, Luca, et al.
Publicado: (2023)

Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PL(pro) and M(pro)/ 3CL(pro): molecular docking and simulation studies of three pertinent medicinal plant natural components
por: Verma, Devvret, et al.
Publicado: (2021)

In silico screening of potential compounds from begonia genus as 3CL protease (3Cl pro) SARS-CoV-2 inhibitors
por: Maulana, Saipul, et al.
Publicado: (2023)

Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2
por: Tahir ul Qamar, Muhammad, et al.
Publicado: (2020)

Discovery of PL(pro) and M(pro) Inhibitors for SARS-CoV-2
por: Puhl, Ana C., et al.
Publicado: (2023)

Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches
por: Tahir ul Qamar, Muhammad, et al.
Publicado: (2020)

Network Pharmacology Approach for Medicinal Plants: Review and Assessment
por: Noor, Fatima, et al.
Publicado: (2022)

Target-Specific Machine Learning Scoring Function Improved Structure-Based Virtual Screening Performance for SARS-CoV-2 Drugs Development
por: Tahir ul Qamar, Muhammad, et al.
Publicado: (2022)

Discovery of SARS-CoV-2 3CL(Pro) Peptidomimetic Inhibitors through the Catalytic Dyad Histidine-Specific Protein–Ligand Interactions
por: Wang, Yaxin, et al.
Publicado: (2022)

Discovery of Rift Valley fever virus natural pan-inhibitors by targeting its multiple key proteins through computational approaches
por: Fatima, Israr, et al.
Publicado: (2022)

MAPS Database: Medicinal plant Activities, Phytochemical and Structural Database
por: Ashfaq, Usman Ali, et al.
Publicado: (2013)

Characterization of trans‐ and cis‐cleavage activity of the SARS coronavirus 3CL(pro) protease: basis for the in vitro screening of anti‐SARS drugs
por: Lin, Cheng-Wen, et al.
Publicado: (2004)

Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition
por: Ryu, Young Bae, et al.
Publicado: (2010)

Machine learning prediction of 3CL(pro) SARS-CoV-2 docking scores
por: Bucinsky, Lukas, et al.
Publicado: (2022)

Prioritisation of Compounds for 3CL(pro) Inhibitor Development on SARS-CoV-2 Variants
por: Jukič, Marko, et al.
Publicado: (2021)

Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases
por: Jade, Dhananjay, et al.
Publicado: (2021)

Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M(pro)/3CL(pro) in Living Cells
por: Moghadasi, Seyed Arad, et al.
Publicado: (2022)

Discovery of naturally occurring inhibitors against SARS-CoV-2 3CL(pro) from Ginkgo biloba leaves via large-scale screening
por: Xiong, Yuan, et al.
Publicado: (2021)

Discovery and characterization of the covalent SARS-CoV-2 3CL(pro) inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches
por: Zhang, Ya-Ni, et al.
Publicado: (2023)

Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CL(Pro)) Activity
por: Guijarro-Real, Carla, et al.
Publicado: (2021)

Potential medicinal plants involved in inhibiting 3CL(pro) activity: A practical alternate approach to combating COVID-19
por: Yang, Fan, et al.
Publicado: (2022)

Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CL(pro) inhibitors
por: Nukoolkarn, Veena, et al.
Publicado: (2008)

Human Superantibodies to 3CL(pro) Inhibit Replication of SARS-CoV-2 across Variants
por: Glab-ampai, Kittirat, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9hueplktkkjk1vo2t2sae06n54